Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filippo Pietrantonio

Showing results (211-220 of 323) with videos related to

Pageof 33
Sort By:
JCO Precision Oncology|November 10, 2022
Circulating Tumor DNA as a Marker of Minimal Residual Disease After Radical Resection of Colorectal Liver MetastasesFederica Marmorino, Michele Prisciandaro, Mirella Giordano, et al.
Journal for Immunotherapy of Cancer|June 5, 2023
Outcomes and a prognostic classifier in patients with microsatellite instability-high metastatic gastric cancer receiving PD-1 blockadeGiovanni Randon, Yu Aoki, Romain Cohen, et al.
European Journal of Cancer (Oxford, England : 1990)|August 11, 2024
Sunitinib for the treatment of patients with advanced pheochromocytomas or paragangliomas: The phase 2 non-randomized SUTNET clinical trialVincenzo Nasca, Natalie Prinzi, Jorgelina Coppa, et al.
International Journal of Cancer|June 9, 2022
Early onset metastatic colorectal cancer in patients receiving panitumumab-based upfront strategy: Overall and sex-specific outcomes in the Valentino trialAlessandra Raimondi, Giovanni Randon, Michele Prisciandaro, et al.
Nature Communications|December 9, 2016
Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancerBeth O Van Emburgh, Sabrina Arena, Giulia Siravegna, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 22, 2025
CtDNA detection with low-pass whole genome bisulfite sequencing in RAS wild-type metastatic colorectal cancer: an exploratory objective of the VALENTINO trialPaolo Manca, Marta Paoli, Francesca Galardi, et al.
European Journal of Cancer (Oxford, England : 1990)|July 21, 2025
Prognostic impact of the BRAF V600E mutation in patients with MSI-high metastatic colorectal cancer treated with immune checkpoint inhibitorsClaire Gallois, Margherita Ambrosini, Sara Lonardi, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 9, 2015
A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancerFilippo Pietrantonio, Giuseppe Aprile, Lorenza Rimassa, et al.
Nature Communications|March 25, 2026
First-line Nivolumab plus FOLFOXIRI/Bevacizumab in advanced RAS/BRAF-mutated colorectal cancer: efficacy, safety and biomarker discovery from the phase II NIVACOR trialAngela Damato, Riziero Esposito Abate, Simona Tessitore, et al.
The New England Journal of Medicine|June 1, 2026
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic CancerEileen M O'Reilly, Zev A Wainberg, Andrew E Hendifar, et al.
Pageof 33

Showing results (211-220 of 323) with videos related to

Sort By:
Pageof 33
JCO Precision Oncology|November 10, 2022
Circulating Tumor DNA as a Marker of Minimal Residual Disease After Radical Resection of Colorectal Liver MetastasesFederica Marmorino, Michele Prisciandaro, Mirella Giordano, et al.
Journal for Immunotherapy of Cancer|June 5, 2023
Outcomes and a prognostic classifier in patients with microsatellite instability-high metastatic gastric cancer receiving PD-1 blockadeGiovanni Randon, Yu Aoki, Romain Cohen, et al.
European Journal of Cancer (Oxford, England : 1990)|August 11, 2024
Sunitinib for the treatment of patients with advanced pheochromocytomas or paragangliomas: The phase 2 non-randomized SUTNET clinical trialVincenzo Nasca, Natalie Prinzi, Jorgelina Coppa, et al.
International Journal of Cancer|June 9, 2022
Early onset metastatic colorectal cancer in patients receiving panitumumab-based upfront strategy: Overall and sex-specific outcomes in the Valentino trialAlessandra Raimondi, Giovanni Randon, Michele Prisciandaro, et al.
Nature Communications|December 9, 2016
Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancerBeth O Van Emburgh, Sabrina Arena, Giulia Siravegna, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 22, 2025
CtDNA detection with low-pass whole genome bisulfite sequencing in RAS wild-type metastatic colorectal cancer: an exploratory objective of the VALENTINO trialPaolo Manca, Marta Paoli, Francesca Galardi, et al.
European Journal of Cancer (Oxford, England : 1990)|July 21, 2025
Prognostic impact of the BRAF V600E mutation in patients with MSI-high metastatic colorectal cancer treated with immune checkpoint inhibitorsClaire Gallois, Margherita Ambrosini, Sara Lonardi, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 9, 2015
A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancerFilippo Pietrantonio, Giuseppe Aprile, Lorenza Rimassa, et al.
Nature Communications|March 25, 2026
First-line Nivolumab plus FOLFOXIRI/Bevacizumab in advanced RAS/BRAF-mutated colorectal cancer: efficacy, safety and biomarker discovery from the phase II NIVACOR trialAngela Damato, Riziero Esposito Abate, Simona Tessitore, et al.
The New England Journal of Medicine|June 1, 2026
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic CancerEileen M O'Reilly, Zev A Wainberg, Andrew E Hendifar, et al.
Pageof 33